RecruitingNCT03092180
Optimizing Treatment on Idiopathic Inflammatory Myopathies
Sponsor
University of Sao Paulo
Enrollment
60 participants
Start Date
Jan 1, 2005
Study Type
OBSERVATIONAL
Conditions
Summary
As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset. This scheme is an internal routine protocol of our Service.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Idiopathic inflammatory myopathies
Exclusion Criteria1
- Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies, overlapped myopathies, others myopathies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGIntravenous Infusion
Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03092180
Related Trials
A Study of AZD0120 in Autoimmune Diseases
NCT0729584718 locations
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT0691680635 locations
MTS109 in Patients With Refractory Autoimmune Diseases
NCT075263501 location
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT0673393515 locations
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT0666525655 locations